{
    "nct_id": "NCT06724016",
    "official_title": "A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390 in Patients with Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Have a histologically and/or cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit.\n* Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patients for Dose-Ranging and Dose-Expansion Part must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Age of 18 years or older (or country's legal age of majority if the legal age was >18 years)\n* Adequate renal function.\n* Adequate hematologic function.\n* Adequate liver function.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received prior treatment with agent targeting the IL-2, IL-7, or IL-15 receptors, or related to mode of action of HM16390.\n* Known active CNS metastases and/or carcinomatous meningitis.\n* History of severe toxicities associated with a prior immunotherapy.\n* Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade â‰¤ 1 per CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.\n* Has ongoing or suspected autoimmune disease.\n* Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.\n* History of chronic liver disease or evidence of hepatic cirrhosis.",
    "miscellaneous_criteria": "Key"
}